Vericel on Track for Over 30% MACI Growth in 2021

Vericel's MACI orthobiologic

Vericel reported 4Q20 orthopedic revenue of USD $34.7 million, +3.2% vs. 4Q19 with full-year 2020 revenue of $94.4 million, +3.1% vs. 2019. Both totals represent record revenue performance for the company.

Vericel expects 2021 MACI growth in the low- to mid-30% range. The guidance assumes the company can grow its base of surgeons taking...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us